| DE | 0-10763 | 63-0821819 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| One Allentown Parkway, Allen, Texas | 75002 | |
| (Address of principal executive offices) | (Zip Code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 4, 2016 |
Atrion Corporation By: /s/ David Battat David Battat President and CEO |
| Exhibit No. | Description | |
| 99.1 | Press Release of Atrion Corporation dated May 4, 2016 |
ALLEN, TX -- (Marketwired - May 04, 2016) - Atrion Corporation (NASDAQ: ATRI) today announced diluted earnings per share for the first quarter of 2016 were $3.76 as compared to $4.01 in the first quarter of 2015. Revenues for the quarter ended March 31, 2016 were $36.2 million compared with $38.3 million in the same period in 2015. Net income in the current-year quarter totaled $6.9 million compared to $7.6 million in last year's first quarter.
Commenting on the Company's results for the first quarter of 2016 compared to the same period last year, David A. Battat, President & CEO, said, "The first quarter of this year saw a 6% decline in sales and earnings per diluted share. As discussed in prior releases, the strong U.S. dollar, coupled with the commoditization of one of our Ophthalmic products, will cause some quarters to compare unfavorably to their 2015 counterparts. Full year results should be comparable to the prior year." Mr. Battat continued, "While the macroeconomic environment remains challenging, we remain confident in our medium and long-term growth prospects. The timing of customer validations of current and future products should lead to solid growth in revenues and operating income in 2017 and beyond. To position ourselves for this growth, we are currently in the planning stage of a substantial expansion of our manufacturing footprint and capabilities." Mr. Battat concluded, "During the quarter, we purchased 3,427 shares of our common stock at an average price of $372 per share in keeping with our disciplined practice of returning excess capital to stockholders through repurchases if, and only if, shares are available at favorable values."
Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com.
Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding comparisons of results for quarters in 2016 with 2015 quarters, results for full year 2016 compared to full year 2015, medium and long-term growth prospects and the Company's growth in revenues and operating income in 2017 and beyond. Words such as "expects," "believes," "anticipates," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve risks and uncertainties. The following are some of the factors that could cause actual results or future events to differ materially from those expressed in or underlying our forward-looking statements: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; the Company's ability to protect its intellectual property; changes in the prices of raw materials; changes in product mix; and intellectual property and product liability claims and product recalls. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission.
ATRION CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
(Unaudited)
Three Months Ended March 31,
2016 2015
------------- -------------
Revenues $ 36,215 $ 38,324
Cost of goods sold 18,650 19,800
------------- -------------
Gross profit 17,565 18,524
Operating expenses 7,100 7,038
------------- -------------
Operating income 10,465 11,486
Interest income 123 177
Other income (expense), net (345) --
------------- -------------
Income before income taxes 10,243 11,663
Income tax provision (3,298) (4,061)
------------- -------------
Net income 6,945 7,602
============= =============
Income per basic share $ 3.81 $ 4.05
============= =============
Weighted average basic shares outstanding 1,823 1,875
============= =============
Income per diluted share $ 3.76 $ 4.01
============= =============
Weighted average diluted shares outstanding 1,849 1,895
============= =============
ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
Mar. 31, Dec. 31,
ASSETS 2016 2015
------------- -------------
(Unaudited)
Current assets:
Cash and cash equivalents $ 27,947 $ 28,346
Short-term investments 39 44
------------- -------------
Total cash and short-term investments 27,986 28,390
Accounts receivable 21,717 16,620
Inventories 30,468 29,771
Prepaid expenses and other 1,372 2,934
Deferred income taxes 580 580
------------- -------------
Total current assets 82,123 78,295
Long-term investments 11,092 9,866
Property, plant and equipment, net 64,112 63,314
Other assets 12,860 12,861
------------- -------------
$ 170,187 $ 164,336
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities 11,038 9,316
Line of credit -- --
Other non-current liabilities 10,597 10,922
Stockholders' equity 148,552 144,098
------------- -------------
$ 170,187 $ 164,336
============= =============
Contact: Jeffery Strickland Vice President and Chief Financial Officer (972) 390-9800